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OBJECTIVE—To assess the impact of continuous glucose monitoring on hypoglycemia in
people with type 1 diabetes.
RESEARCH DESIGN AND METHODS—In this randomized, controlled, multicenter
study, 120 children and adults on intensive therapy for type 1 diabetes and a screening level of
glycated hemoglobin A1c (HbA1c) ,7.5% were randomly assigned to a control group performing
conventionalhomemonitoringwithabloodglucosemeterandwearingamaskedcontinuousglucose
monitoreverysecondweekforﬁvedaysortoagroupwithreal-timecontinuousglucosemonitoring.
The primary outcome was the time spent in hypoglycemia (interstitial glucose concentration ,63
mg/dL) over a period of 26 weeks. Analysis was by intention to treat for all randomized patients.
RESULTS—The time per day spent in hypoglycemia was signiﬁcantly shorter in the contin-
uous monitoring group than in the control group (mean 6 SD 0.48 6 0.57 and 0.97 6 1.55
h/day, respectively; ratio of means 0.49; 95% CI 0.26–0.76; P = 0.03). HbA1c at 26 weeks was
lower in the continuous monitoring group than in the control group (difference 20.27%; 95%
CI 20.47to20.07; P=0.008).Timespent in70to180mg/dLnormoglycemia wassigniﬁcantly
longer in the continuous glucose monitoring group compared with the control group (mean
hours per day, 17.6 vs. 16.0, P =0 . 0 0 9 ) .
CONCLUSIONS—Continuous glucose monitoring was associated with reduced time spent
in hypoglycemia and a concomitant decrease in HbA1c in children and adults with type 1 di-
abetes.
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T
he beneﬁts of intensive treatment of
type 1 diabetes, established almost
20 years ago (1), are difﬁcult to ach-
ieve, despite the increased use of insulin
analogs and insulin pumps, with only a
minorityofpatientsmaintainingtheirgly-
cated hemoglobin A1c (HbA1c)w i t h i nt h e
target range (2). Intensive insulin treat-
ment and lower HbA1c increase exposure
to hypoglycemia (3,4). The risk
of hypoglycemia is even higher in chil-
dren and adolescents (5,6) and increases
with the duration of diabetes (7). Fre-
quent hypoglycemia is associated with
hypoglycemia unawareness (8,9), which
mayinturnleadtoreducedadherenceto
therapeutic decisions (10). Finally, hy-
poglycemia may be associated with per-
manent damage to the central nervous
system (11) and may permanently inﬂu-
ence cognitive functions in children
(12) but not in adults (13).
Recently, devices for real-time con-
tinuous glucose monitoring have been
introduced to aid self-management of
glycemic control and have been shown
to improve HbA1c levels in people with
type 1 diabetes (14–17).Inclinicalpractice
recommendations,ithasalsobeensugges-
ted that continuous glucose monitoring is
especially useful in patients with hypogly-
cemia unawareness and/or frequent epi-
sodes of hypoglycemia (18). However,
thehypoglycemiapreventiveeffectofcon-
tinuous glucose monitoring has not been
established.Therefore,wedesignedaran-
domized, controlled, multicenter clinical
trial to evaluate the effect of continuous
glucose monitoring on hypoglycemia in
children and adults with type 1 diabetes.
RESEARCH DESIGN AND
METHODS
Patients
Patients aged between 10 and 65 years
with type 1 diabetes diagnosed for more
than 1 year, with reasonable metabolic
controlassessingcarbohydrateintakeand
self-adjusting insulin, and an HbA1c level
,7.5%, using intensive insulin treatment
with either an insulin pump or multiple
daily injections, and not using a real-time
continuousglucosemonitoringdevicefor
atleast4weekswereeligibleforthestudy.
All eligible patients identiﬁed from the
local diabetes registries were invited to
participate and screened consecutively
based on the order of their positive reply.
The study protocol was designed by
the researchers and approved by the in-
stitutional or national medical ethics
committees from all three centers, and
the conduct of the study was consistent
with the Good Clinical Practice provi-
sions of the Declaration of Helsinki with
all amendments and local regulatory re-
quirements. A written informed consent
wasobtainedfromallparticipantsandpa-
rents of minors (under 18 years of age,
who signed an assent) before enrollment.
At screening patients provided a
blood sample for measurement of HbA1c
and entered a 4-week run-in period dur-
ing which self-monitoring of blood glu-
cose (SMBG) was conducted according
to patients’ standard glycemic manage-
ment regimen. A FreeStyle blood glucose
meter (Abbott Diabetes Care, Alameda,
CA) was provided to familiarize patients
with FreeStyle test stripsand collect base-
line SMBG frequency and glucose levels.
Diaries were distributed for recording
events of hypoglycemia and associated
food intake, insulin doses, and exercise.
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ORIGINAL ARTICLEAllpatientsmeetingtheeligibilitycriteria,
includingHbA1cresultfromthescreening
visit, were invited to attend the randomi-
zation visit.
Study design
Following the 1-month run-in period,
patients were randomized to participate
in a 6-month intervention period. Pa-
tients were assigned to home monitoring
with a FreeStyle blood glucose meter
and a masked continuous glucose moni-
tor to be worn for 5 days every second
week (control group) or to a group with
real-time continuous glucose monitoring,
wearing individual sensors for 5 days
continuously for 26 weeks (continuous
monitoring group). Patients and investi-
gators were masked for the continuous
glucose monitoring data in the control
group. Patients were allocated to either
group by permuted block randomization
stratiﬁed according to age (10 to 17 years
pediatric, 18 to 65 years adult) and study
center. The randomization sequence was
computergenerated,andallocationswere
concealed using envelopes. Both groups
were provided with the FreeStyle Navi-
gator (Abbott Diabetes Care), a continu-
ous glucose monitoring system that
measures glucose in interstitial ﬂuid.
All patients were trained to insert and
calibrate subcutaneous sensors and to
operate the continuous monitoring de-
vice. Patients in the continuous monitor-
ing group were instructed in the use of
real-time glucose readings; however, no
written guidelines were given on adjust-
ment of diabetes management based on
the real-time readings. Patients also in-
dividually set their glucose alarms. All
patients were encouraged to maintain
their blood glucose concentration within
the preprandial target range of 70 to 130
mg/dL with peak postprandial values
below 180 mg/dL.
The ﬁrst subcutaneous sensor was
inserted upon randomization at visit 2
(day 1). The schedule of follow-up visits
was identical for both groups. All patients
returnedforavisit2–6daysafterrandom-
izationforuploadofalldevicestoconﬁrm
that continuous data were recorded and
to replace the subcutaneous sensor under
supervision. Further visits were con-
ducted at days 60, 120, and 180 (67
days). Data were uploaded at each visit,
and adverse events including severe hypo-
glycemia (19), hyperglycemia resulting in
ketoacidosis requiring intravenous ﬂuids,
device-related or study-related untoward
events, and serious adverse events regard-
less of cause, were reviewed and reported.
Diabetes self-management was ad-
justed by patients based on the blood
glucose measurements in the control
group and blood glucose measurements
and continuous glucose data in the con-
tinuous glucose monitoring group. Sam-
ples for HbA1c were collected at days 1,
60, and 180. All samples for HbA1c were
senttoacentrallaboratory(Laboratorium
Klinische Forschung, Kiel, Germany; mea-
surement by Bio-Rad Variant II Turbo ana-
lyzer, Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
The primary outcome was time spent in
hypoglycemia (,63 mg/dL) during the
26-week study period. A sample size of
120patients wasplanned to haveapower
of 80% to detect a difference in the time
spent in hypoglycemia between study
groups, assuming a population difference
of 42%, a SD of 1.12, an a-level of 0.05,
andalosstofollow-upofnomorethan17%.
All analyses were performed ac-
cording to the intent-to-treat principle,
including all data collected for patients
that discontinued prematurely. An excur-
sion was deﬁned as all consecutive re-
cordings outside the boundary covering
at least 10 min. The duration of an
excursion was deﬁned as the elapsed
time from ﬁrst excursion to the ﬁrst
reading indicating return inside the ex-
cursion boundary. Continuous glucose
monitoring data in both groups were used
to estimate the amount of time per day the
glucose level was hypoglycemic (,63
mg/dL,,70mg/dL,or,55mg/dL),hyper-
glycemic (.180 mg/dL or .250 mg/dL),
and in the target range (70 to 180 mg/dL
or 90 to 180 mg/dL) for each patient. The
number of hypoglycemic excursions (,55
and ,63 mg/dL) per day and separately
during the night period of 0000–0600 h
was also calculated. The risk associated
with glucose concentration outside the
recommended range was assessed by cal-
culating low blood glucose indexes
(LBGIs) and high blood glucose indexes
(HBGIs) (20). Comparisons between
study groups were performed with the
use of the Mann-Whitney U test. CIs for
Table 1—Baseline characteristics of the patients
Control
group
Continuous
monitoring group
N 58 62
Female sex, number (%) 19 (33) 26 (42)
Age (years)* 26.0 6 14.6 25.7 6 14.1
Pediatric, number (%) 26 (45) 27 (44)
BMI (kg/m
2)* 22.0 6 3.8 22.4 6 3.8
Duration of diabetes (years)* 11.4 6 11.4 11.6 6 11.3
Insulin administration, number (%)
Pump 34 (59) 47 (76)
MDI 24 (41) 15 (24)
Glycated hemoglobin at screening (%)* 6.90 6 0.47 6.83 6 0.44
Glycated hemoglobin at baseline (%)* 6.91 6 0.67 6.92 6 0.56
Record of severe hypoglycemia in
last year, number (%) 7 (12) 5 (8)
Diagnosed with hypoglycemia
unawareness, number (%) 4 (7) 6 (10)
Daily insulin dose (units/kg)* 0.67 6 0.32 0.66 6 0.25
Education, number (%)
Pediatric patient still in education 26 (45) 29 (47)
Completed education by age 18 3 (5) 6 (10)
Completed further education 29 (50) 27 (44)
Prior use of continuous glucose monitor,
number (%) 18 (31) 21 (34)
Mean blood glucose in 1-month run-in
period (mg/dL)* 148 6 28 147 6 23
SMBG measurements per day in 1-month
run-in period* 5.1 6 2.5 5.3 6 2.2
Differencesbetweenthecontrolandthe continuousmonitoringgroupwere notstatistically signiﬁcant.MDI,
multiple daily injection. *Means 6 SD.
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tinuous monitoring/control) were calcu-
lated using the bias-corrected accelerated
(BCa) bootstrap method. A P value of less
than 0.05 (two-sided test) was considered
to indicate statistical signiﬁcance.
Comparison between the two study
groupsofHbA1clevelsatdays60and180
was performed using ANCOVA on base-
line HbA1c level and adjusted for clinical
center and adult or pediatric patient.
Missing HbA1c data were imputed using
the last-observation-carried-forward
method, including patients that discon-
tinued prematurely.
Analyseswereconductedwiththeuse
of SAS software, version 8.02 (SAS In-
stitute, Cary, NC). All P values were two-
sided.
All researchers had full access to the
whole database after it was locked.
RESULTS
Patients
In the period from October 2008 to May
2009,122eligiblepatientswerescreened.
Ofthese,twopatients droppedout before
randomization, and 58 were randomized
to the control and 62 were randomized to
the continuous glucose monitoring
group. The study was completed by 48
patients (83%) and 53 patients (85%),
respectively. The study ﬂowchart is de-
picted in Supplementary Fig. 1. Patient
baseline characteristics are summarized
in Table 1.
During the one-month run-in period,
the mean concentration and frequency of
home blood glucose monitoring was sim-
ilar in the control and continuous mon-
itoring groups (Table 1). Mean HbA1c
measured at the end of the run-in period
before randomization was 6.9 6 0.7 and
6.9 6 0.6%, respectively.
In the six-month randomized study
period, median sensor wear was 5.6
(pediatric 5.6, adults 4.9) and 6.1 (pedi-
atric 6.1, adults 6.1) days per week of
instructed use in the control and contin-
uous monitoring groups, respectively.
Median sensor wear in the continuous
monitoring group in month 6 was 5.9
days per week. Detailed data on sensor
wear are presented in Supplementary
Table 1 and Supplementary Figs. 2 and 3.
Hypoglycemia
The primary outcome, time spent in
hypoglycemia below 63 mg/dL, was sig-
niﬁcantly shorter in the continuous glu-
cose monitoring group (ratio of means
0.49 [95% CI 0.26–0.76], P = 0.03)
(Supplementary Fig. 4). Similarly, time
spent in hypoglycemia below 70 mg/dL
and below 55 mg/dL was statistically sig-
niﬁcantly shorter in the continuous
glucose monitoring group (P =0 . 0 1a n d
P = 0.05, respectively; Table 2). The re-
duction in the primary outcome was evi-
dent from the ﬁrst month and was
sustained throughout the 6 months
(Fig. 1).
The integrated glucose excursion in-
dex for ,63 mg/dL was reduced in the
continuous monitoring group (P = 0.02)
as was the low blood glucose index (P =
0.02).Althoughnotstatisticallysigniﬁcant,
the number of hypoglycemic excursions
(,55 and ,63 mg/dL) per 24 h/day was
also lower in the continuous monitoring
group (P =0 . 0 7a n dP = 0.08, respec-
tively). The number of hypoglycemic ex-
cursions ,55 and ,63 mg/dL during the
night, however, was signiﬁcantly lower in
the continuous monitoring group com-
pared with the control (0.13 6 0.30 vs.
0.1960.19,P=0.01;and0.2160.32vs.
0.30 6 0.31, P = 0.009).
Time spent in hypoglycemia below
63 mg/dL was reduced in the continuous
monitoring group by 41% (mean 0.48 vs.
0.81 h/day) in pump users and by 59%
(0.49 vs. 1.20) in subjects on multiple
daily injections. This end point was re-
duced by 48% (0.34 vs. 0.65) in pediat-
ric subjects (10–17 years of age) and by
54% (0.59 vs. 1.27) in adults (18–65
years of age). In the post hoc per protocol
analysis, where only patients that wore
the sensor for .20 days (corresponding
Table 2—Glycemic outcomes
Variable
Control
group
Continuous
monitoring group
Ratio of
means
95% CI for
ratio of means P
N 54 62
Hours per day in hypoglycemia ,63 mg/dL 0.97 6 1.55 0.48 6 0.57 0.49 0.26–0.76 0.03
Median (interquartile range) 0.54 (0.23–1.31) 0.26 (0.14–0.54)
Number of hypoglycemic excursions per day
,63 mg/dL 0.76 6 0.94 0.53 6 0.60 0.70 0.43–1.03 0.08
Integrated glucose excursion index (area under
the curve) ,63 mg/dL 11.1 6 14.2 5.4 6 7.6 0.49 0.29–0.79 0.02
Hours per day in hypoglycemia ,55 mg/dL 0.41 6 0.48 0.22 6 0.34 0.55 0.34–0.91 0.05
Number of hypoglycemic excursions per day
,55 mg/dL 0.37 6 0.40 0.28 6 0.54 0.76 0.47–1.43 0.07
Hours per day in hypoglycemia ,70 mg/dL 1.60 6 2.02 0.91 6 0.81 0.57 0.36–0.80 0.01
Low blood glucose index 1.74 6 1.62 1.18 6 0.82 0.68 0.49–0.89 0.02
Hours per day in hyperglycemia
.180 mg/dL 6.4 6 3.4 5.5 6 3.2 0.86 0.71–1.06 0.08
.250 mg/dL 1.66 6 1.53 1.14 6 1.46 0.69 0.48–1.07 0.06
High blood glucose index 6.0 6 3.2 5.1 6 3.1 0.85 0.70–1.05 0.05
Hours per day in normoglycemia
90–180 mg/dL 13.5 6 3.1 15.1 6 2.7 1.12 1.04–1.21 0.003
70–180 mg/dL 16.0 6 3.4 17.6 6 3.2 1.10 1.02–1.18 0.009
Dataaremeans6SD.Anexcursionisdeﬁnedasallconsecutiverecordingsoutsidetheboundaryandcoveringatleast10min.Thedurationofanexcursionisdeﬁned
as the elapsed time from ﬁrst excursion to the ﬁrst reading indicating return inside the excursion boundary.
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Battelino and Associatesto one third of the required time in the
control group) were included (44 of 53
pediatric and 53 of 63 adult patients),
the primary outcome was reduced by
64% (P , 0.001) and 50% (P = 0.02) in
pediatric and adult patients, respectively.
Glycated hemoglobin and glycemic
control
HbA1c at 6 months, adjusted for baseline
HbA1c (visit 2), center and age-group was
signiﬁcantly lower in the continuous glu-
cose monitoring group (mean 6.69%
compared with 6.95%, difference in
means 20.27, 95% CI 20.47 to 20.07,
P = 0.008) (Fig. 2). Mean HbA1c at 6
months,adjustedforbaselineHbA1c,cen-
terandage-group,wasreducedby0.39in
pump users (6.72 vs. 7.11). For subjects
using multiple daily injections, the differ-
ence was 20.06 (6.70 vs. 6.65). Adjusted
mean HbA1c was reduced by 0.23 (6.92
vs. 7.15) in pediatric subjects (10–17
years of age) and by 0.31 (6.51 vs. 6.83)
in adults (18–65 years of age).
Time spent in normoglycemia (70 to
180 mg/dL and 90 to 180 mg/dL) was
signiﬁcantly longer in the continuous
glucose monitoring group (mean hours
perday,17.6vs.16.0,P=0.009;and15.1
vs. 13.5, P = 0.003). Concurrently, the
time spent per day in hyperglycemia
.250mg/dLwasshorterinthecontinuous
monitoring group compared with control
group (mean hours per day, 1.14 and
1.66), although this was not statistically
signiﬁcant.
Adverse events
Fourseriousadverseeventswerereported
although none were related to the study
or device (Supplementary Table 2). There
was an incident of mild diabetic ketoaci-
dosis(DKA)inapatientinthecontinuous
monitoring group, because of the patient
disconnecting his or her insulin pump.
However, this patient had stopped wear-
ing the continuous glucose monitoring
system 2 weeks before the incident. No
incidentsofsevere hypoglycemiawerere-
ported.
CONCLUSIONS—This randomized
controlled trial, designed to evaluate the
effect of continuous glucose monitoring
on hypoglycemia in type 1 diabetes,
demonstrated a signiﬁcant reduction by
half in time spent in hypoglycemia in
relatively well-controlled children and
adults with type 1 diabetes. Notably,
thisﬁndingwasparalleled by a signiﬁcant
decrease in HbA1c, contrary to the results
intheDiabetesControlandComplication
Trial (DCCT) study where the rate of hy-
poglycemia increased considerably with
lower HbA1c levels (21).
In the Juvenile Diabetes Research
Foundation (JDRF) trial in children and
adultswithHbA1c,7%atrandomization
(15), hypoglycemia below 60 mg/dL was
less pronounced in the continuous mon-
itoring group than in the control group at
the end of 6 months (median 18 vs. 35
min/day, P = 0.05). Moreover, combined
outcomes of hypoglycemia and HbA1c
were signiﬁcantly better in the continu-
ous glucose monitoring patients than in
the control patients, which corroborate
our ﬁndings.
A recent randomized controlled trial
named Sensor-Augmented Pump Ther-
apy for A1C Reduction 3 (STAR 3) com-
paring sensor-augmented pump therapy
with multiple-injection therapy dem-
onstrated a signiﬁcant reduction of
HbA1c in adults and children without an
increase in hypoglycemia (22). However,
the area under the curve ,70 mg/dL and
,50 mg/dL did not differ between the
two treatment modalities. It is possible
thattherelativelysmallamountofcontin-
uoussensor data inthe multiple-injection
therapy group lacked sufﬁcient power to
show a difference. Additionally, the base-
line HbA1c was considerably higher in the
STAR3trialascomparedwiththecurrent
study.
None of the participants or parents in
the current study reported an event of
severe hypoglycemia. Similarly, severe
hypoglycemia episodes were infrequent
in the JDRF trial (less than 10% of the
p a t i e n t s )( 1 5 )a n dt h eS T A R3t r i a l
(around 13 per 100 patient-years) (22)
and did not differ between the study
groups. Neither the JDRF trial nor ours
was powered to detect differences in
t h er a t eo fs e v e r eh y p o g l y c e m i ce p i s o d e s .
In the open extension phase of the JDRF
trial, episodes of severe hypoglycemia
decreased by almost 50% in the control
patients after they were switched to con-
tinuous glucose monitoring, but this was
notstatisticallysigniﬁcant(P=0.08)(16).
Although the number of hypoglyce-
mic excursions below 55 mg/dL was not
signiﬁcantly different between the two
groups per 24 h, itwassigniﬁcantly lower
in the continuous monitoring group dur-
ing the night. In the JDRF trial, a higher
incidence of nocturnal hypoglycemia is
associated with lower HbA1c in the con-
tinuous glucose monitoring group; how-
ever, no comparison is made with the
control group (23). Taken together, pre-
vious and present data may suggest that
the risk of hypoglycemia is alleviated by
continuous glucose monitoring. Clinically
more meaningful reduction of hypoglyce-
mic events remains to be demonstrated.
Figure1—Timespentbelow63mg/dLbymonth.Meanvalues6SEsforhoursperdayspent,63
mg/dL over the 6-month study period in all patients. ●, continuous monitoring group; ▲,c on tro l
group.
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Continuous glucose monitoring in type 1 diabetesSeveral studies have demonstrated
that the use of continuous monitoring
above 70% of the time is associated with
signiﬁcantly increased beneﬁt and with a
signiﬁcant lowering of HbA1c in all age
groups (17,22,24). Compliance with the
sensor wear in the current study in the
continuous monitoring group was more
than 6 days per week (86%) and did not
decrease signiﬁcantly with time, with an
averageofaround5.8days/week(84%)at
the end of the 26-week period (Supple-
mentary Fig. 2B). This is roughly similar
to the adult group and considerably more
than the adolescent or children group of
the JDRF trial (16).
This study protocol stated that the
control group should wear a masked
sensor for 5 days every second week,
amounting to 65 days or around 9 weeks
during the 26-week study period. In fact,
compliance with the sensor wear in the
control group was lower than intended
(around80%).However,whencompared
with previous studies, the amount of
masked continuous monitoring data
from the control group was substantial.
Combined with the high compliance of
sensor use in the continuous monitoring
group, this contributed to the power of
the statistical analysis.
Our results must be interpreted with
caution since the patients and their fam-
ilies were highly motivated, demonstrat-
ing good metabolic control with an
average of more than ﬁve blood glucose
measurements per day before randomi-
zation, and all three participating centers
were academic with high penetration of
diabetes-related technology. Addition-
ally, because of its nature, the interven-
tion could not be blinded, rendering the
results less compelling. The results may
therefore not be simply generalized, and
further studies are needed to evaluate the
hypoglycemia-preventive effects of con-
tinuous glucose monitoring in less well-
controlled and less motivated patient
populations.
In conclusion, the results of the cur-
rent study demonstrated signiﬁcantly
shorter time spent in hypoglycemia in
children and adults with type 1 diabetes
who used continuousglucose monitoring
compared with standard SMBG, with a
concomitant signiﬁcant decrease of
HbA1c.
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